HAIFA, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical–stage biotechnology company developing novel therapies to treat [...] Read more »
Nilo Therapeutics startet mit einer Serie-A-Finanzierung in Höhe von 101 Mio. USD zur Entwicklung einer neuen Medikamentenklasse, die auf neuronale Schaltkreise bei Immunerkrankungen abzielt, und ernennt Kim Seth zum Chief Executive Officer
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) — Nilo Therapeutics, ein Biotechnologieunternehmen, das neuronale Schaltkreise nutzt, um die Immunhomöostase bei Krankheiten wiederherzustellen, startete heute mit einer [...] Read more »
Lancement de Nilo Therapeutics avec un financement de série A de 101 millions de dollars en vue de développer une nouvelle classe de médicaments ciblant les circuits neuronaux dans les maladies immunitaires, et nomination de Kim Seth au poste de directeur général
NEW YORK, 09 oct. 2025 (GLOBE NEWSWIRE) — Nilo Therapeutics, une société de biotechnologie qui mise sur les circuits neuronaux pour rétablir l’homéostasie immunitaire chez les patients malades, [...] Read more »
Nilo Therapeutics é lançada com financiamento de US $101 milhões da Série A para promover uma nova classe de medicamentos direcionados a circuitos neurais em doenças imunológicas e nomeia Kim Seth como CEO
NOVA YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) — A Nilo Therapeutics, uma empresa de biotecnologia que utiliza circuitos neurais para restaurar a homeostase imunológica em doenças, foi lançada hoje com um [...] Read more »
Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer
NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) — Nilo Therapeutics, a biotechnology company harnessing neural circuits to restore immune homeostasis in disease, launched today with a $101 million Series A financing led by The Column Group [...] Read more »
Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Asset
- Angelini Pharma secures exclusive option to license global development and commercialization rights for SVG1051, a pre–clinical investigational novel compound with broad potential to treat [...] Read more »
Kensana Health Lands $120 million from GEM, Fuelling a Global Plant Based Medicine Revolution
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) — Kensana Health Inc. (“Kensana”) today announced it has entered into a share subscription facility of up to $120 million with GEM Global Yield LLC SCS ("GEM"), a [...] Read more »
Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical–stage biotechnology company developing novel therapies to treat [...] Read more »
Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and Abaloparatide
[...] Read more »Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach
- Funding supports next–generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug–repurposing
- Read more »